[摘要]　目的：研究长春瑞宾（NVB）联合顺铂（DDP）方案（NP方案）治疗晚期非小细胞肺癌（NSCLC）的疗效及毒副作用。

方法：91例经病理或细胞学诊断非小细胞肺癌患者，其中腺癌56例，鳞癌27例，肺泡细胞癌4例，大细胞肺癌3例；细胞学涂片为癌细胞1例。初治80例，复治11例；Ⅲ期32例(Ⅲa期2例，Ⅲb期30例)，Ⅳ期59例，采用长春瑞滨（NVB）25 mg/m²，第1、8天静滴；顺铂（DDP）90~100 mg/m²静滴，21天为1个周期。

结果：部分缓解（PR）37例，稳定（SD） 30例，进展（PD） 24例，总有效率为40.6%（95%CI:30.5%~50.7%）。中位进展期5月（95%CI:4~6月），中位生存期13月(95%CI:11~15月)，一年生存率52.7%（95%CI:42.4%~62.9%）。WHO Ⅲ Ⅳ度白细胞下降占40.7%，为主要血液毒性。

结论：长春瑞滨联合顺铂治疗晚期NSCLC疗效确切，毒副反应性可耐受，价格适中，为符合国情的治疗晚期非小细胞肺癌的方案。

[关键词]　晚期非小细胞肺癌；长春瑞滨；顺铂；化疗

[Abstract]　Purpose：To evaluate the efficacy and toxicity of vinorelbine combined with cisplatin (NP regimen) in the treatment of advanced non-small-cell lung cancer (NSCLC).

Methods：ninety-one patients with advanced NSCLC were confirmed by pathology or cytology. There were 56 patients with lung adenocarcinoma, 27 with squamous carcinoma and 4 with alveoli cell cancer, 3 with large-cell lung cancer,one case diagnosed by cytological smear section.The eighty patients had no prior chemotherapy and 11 were those without received previously chemotherapy. Thirty-two patients had stage Ⅲ disease and 59 had stage Ⅳ.